168 related articles for article (PubMed ID: 7572348)
21. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
22. Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions.
Zini N; Santi S; Ognibene A; Bavelloni A; Neri LM; Valmori A; Mariani E; Negri C; Astaldi-Ricotti GC; Maraldi NM
Exp Cell Res; 1994 Feb; 210(2):336-48. PubMed ID: 8299728
[TBL] [Abstract][Full Text] [Related]
23. Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cells.
Khélifa T; Beck WT
Biochem Pharmacol; 1999 Oct; 58(8):1247-57. PubMed ID: 10487526
[TBL] [Abstract][Full Text] [Related]
24. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
Riou JF; Grondard L; Petitgenet O; Abitbol M; Lavelle F
Biochem Pharmacol; 1993 Sep; 46(5):851-61. PubMed ID: 8396937
[TBL] [Abstract][Full Text] [Related]
25. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Austin CA; Fisher LM
Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
[TBL] [Abstract][Full Text] [Related]
26. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.
Chen CF; He X; Arslan AD; Mo YY; Reinhold WC; Pommier Y; Beck WT
Mol Pharmacol; 2011 Apr; 79(4):735-41. PubMed ID: 21252292
[TBL] [Abstract][Full Text] [Related]
27. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
28. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
29. A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha.
Jensen LH; Renodon-Cornière A; Nitiss KC; Hill BT; Nitiss JL; Jensen PB; Sehested M
Biochem Pharmacol; 2003 Aug; 66(4):623-31. PubMed ID: 12906927
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
31. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
Friche E; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312
[TBL] [Abstract][Full Text] [Related]
32. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines.
Mo YY; Beck WT
Oncol Res; 1997; 9(4):193-204. PubMed ID: 9268990
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
35. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
[TBL] [Abstract][Full Text] [Related]
36. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
37. Drug-sensitivity and DNA-binding of a subform of topoisomerase II alpha in resistant human HL-60 cells.
Boege F; Biersack H; Meyer P
Acta Oncol; 1994; 33(7):799-806. PubMed ID: 7993649
[TBL] [Abstract][Full Text] [Related]
38. A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distribution.
Boege F; Kjeldsen E; Gieseler F; Alsner J; Biersack H
Eur J Biochem; 1993 Dec; 218(2):575-84. PubMed ID: 8269948
[TBL] [Abstract][Full Text] [Related]
39. Altered DNA topoisomerase II in multidrug resistance.
Beck WT; Danks MK; Wolverton JS; Granzen B; Chen M; Schmidt CA; Bugg BY; Friche E; Suttle DP
Cytotechnology; 1993; 11(2):115-9. PubMed ID: 7764055
[TBL] [Abstract][Full Text] [Related]
40. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]